Arylsulfatase B regulates versican expression by galectin-3 and AP-1 mediated transcriptional effects

Oncogene

Volumn 33, Issue 47, 2014, Pages 5467-5476

  Bhattacharyya, S ^a,b   Feferman, L ^a,b   Tobacman, J K ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

chondroitin sulfate; arylsulfatase B; galectin 3; versican; glycosaminoglycan

Indexed keywords

ARYLSULFATASE B, HUMAN; CHONDROITIN SULFATE; CSPG2 PROTEIN, MOUSE; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; GALECTIN-3, HUMAN; LGALS3 PROTEIN, MOUSE; N ACETYLGALACTOSAMINE 4 SULFATASE; TRANSCRIPTION FACTOR AP 1; VCAN PROTEIN, HUMAN; VERSICAN;

AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MOLECULAR GENETICS; MUTANT MOUSE STRAIN; ONCOGENE; PROMOTER REGION; PROSTATE TUMOR; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CHONDROITIN SULFATES; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, FOS; GENES, JUN; HUMANS; MALE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOLECULAR SEQUENCE DATA; N-ACETYLGALACTOSAMINE-4-SULFATASE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTOR AP-1; VERSICANS;

EID: 84887540362     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.483     Document Type: Article

References (41)

1. Bhattacharyya S, Solakyildirim K, Zhang Z, Linhardt RJ, Tobacman JK. Cell-bound IL-8 increases in bronchial epithelial cells following Arylsulfatase B silencing. Am J Respir Cell Mol Biol 2010; 42: 51-61
2. Prabhu SV, Bhattacharyya S, Guzman-Hartman G, Macias V, Kajdacsy-Balla A, Tobacman JK. Extra-lysosomal localization of arylsulfatase B in human colonic epithelium. J Histochem Cytochem 2011; 59: 328-335
3. Feferman L, Bhattacharyya S, Deaton R, Gann P, Guzman G, Kajdacsy-Balla A et al. Potential role of Arylsulfatase B as a biomarker for prostate cancer. Prostate Cancer PD 2013; 16: 277-284
4. Mitsunaga-Nakatsubo K, Kusunoki S, Kawakami H, Akasaka K, Akimoto Y. Cellsurface arylsulfatase A and B on sinusoidal endothelial cells, hepatocytes, and Kupffer cells in mammalian livers. Med Mol Morphol 2009; 42: 63-69
5. Bhattacharyya S, Solakyildirim K, Zhang Z, Linhardt RJ, Tobacman J. Chloroquine reduces arylsulfatase B activity and increases chondroitin 4-sulfate: Implications for mechanisms of action and resistance. Malaria J 2009; 8: 303
6. Bhattacharyya S, Kotlo K, Shukla S, Danziger RS, Tobacman JK. Distinct effects of N-Acetylgalactosamine-4-sulfatase and galactose-6-sulfatase expression on chondroitin sulfate. J Biol Chem 2008; 283: 9523-9530
7. Bhattacharyya S, Tobacman JK. Arylsulfatase B regulates colonic epithelial cell migration by effects on MMP9 expression and RhoA activation. Clin Exp Metastasis 2009; 26: 535-545
8. Bhattacharyya S, Tobacman JK. Steroid sulfatase, arylsulfatases A and B, galactose 6-sulfatase, and iduronate sulfatase in mammary cells and effects of sulfated and non-sulfated estrogens on sulfatase activity. J Steroid Biochem Mol Biol 2007; 103: 20-34
9. Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu ZX et al. Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci 2008; 121: 3083-3091
10. Yoo M, Khaled M, Giubbs KM, Kim J, Kowalewski B, Dierks T et al. Arylsulfatase B improves locomotor function after mouse spinal cord injury. PLoS One 2013; 8: e57415
11. Ferrero GB, Pagliardini S, Veljkovic A, Porta F, Bena C, Tardivo I et al. In vivo specific reduction of arylsulfatase B enzymatic activity in children with cystic fibrosis. Mol Genet Metab 2008; 94: 39
12. Bhattacharyya S, Look D, Tobacman JK. Increased arylsulfatase B activity in cystic fibrosis cells following correction of CFTR. Clin Chim Acta 2007; 380: 122-127
13. Sharma G, Burke J, Bhattacharyya S, Sharma N, Katyal S, Park RL et al. Reduced arylsulfatase B activity in leukocytes from cystic fibrosis patients. Pediatr Pulmonol 2013; 48: 236-244
14. Bhattacharyya S, Kotlo K, Danziger R, Tobacman JK. Arylsulfatase B regulates interaction of chondroitin-4-sulfate and kininogen in renal epithelial cells. Biochim Biophys Acta 2010; 1802: 472-477
15. Kotlo K, Bhattacharyya S, Yang B, Feferman L, Tejaskumar S, Linhardt R et al. Impact of salt exposure on N-Acetylgalactosamine-4-sulfatase (Arylsulfatase B) activity, glycosaminoglycans, kininogen, and bradykinin. Glycoconjugate J 2013; 30: 667-676
16. Bhattacharyya S, Tobacman JK. Hypoxia reduces arylsulfatase B activity and silencing arylsulfatase B replicates and mediates the effects of hypoxia. PLoS One 2012; 7: e33250
17. Iwaki J, Minamisawa T, Tateno H, Kominami J, Suzuki K, Nishi N et al. Desulfated galactosaminoglycans are potential ligands for galectins: evidence from frontal affinity chromatography. Biochem Biophys Res Commun 2008; 373: 206-212
18. Song S, Byrd JC, Mazurek N, Liu K, Koo JS, Bresalier RS. Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1 activation. Gastroenterology 2005; 129: 1581-1591
19. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009; 174: 1515-1523
20. Hann A, Gruner A, Chen Y, Gress TM, Buchholz M. Comprehensive analysis of cellular gaectin-3 reveals no consistent oncogenic function in pancreatic cancer cells. PLoS One 2011; 6: e20859
21. Ricciardelli C, Mayne K, Sykes PJ, Wyaymond WA, McCaul K, Marshall VR et al. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res 1997; 3: 983-992
22. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR et al. Elevated levels of versican but not decorin predict disease progression in earlystage prostate cancer. Clin Cancer Res 1998; 4: 963-971
23. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009; 28: 233-245
24. Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 2003; 63: 4786-4791
25. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010; 126: 640-650
26. Domenzain-Reyna C, Hernández D, Miquel-Serra L, Docampo MJ, Badenas C, Fabra A et al. Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem 2009; 284: 12306-12317
27. Holzberg D, Knight CG, Dittrich-Breiholz O, Schneider H, Dörrie A, Hoffmann E et al. Disruption of the c-JUN-JNK Complex by a cell-permeable peptide containing the c-JUN D domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes. J Biol Chem 2003; 278: 40213-40223
28. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harley E et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994; 372: 107-111
29. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW et al. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One 2010; 5: e13828
30. Wu Y, Chen L, Cao L, Sheng W, Yang BB. Overexpression of the C-Terminal PGM/ versican Domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 2004; 117: 2227-2237
31. Xiang YY, Dong H, Wan Y, Li J, Yee A, Yang BB et al. Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor. J Biol Chem 2006; 281: 19358-19368
32. Roeser D, Preusser-Kunze A, Schmidt B, Gasow K, Wittmann JG, Dierks T et al. A general binding mechanism for all human sulfatases by the formylglycinegenerating enzyme. Proc Natl Acad Sci USA 2006; 103: 81-86
33. Roeser D, Schmidt B, Preusser-Kunze A, Rudolph MG. Probing the oxygen-binding site of the human formylglycine generating enzyme using halide ions. Acta Crystallogr D Biol Crystallogr 2007; 63: 621-627
34. Wò jczyk B. Lysosomal arylsulfatases A and B from horse blood leukocytes: purification and physico-chemical properties. Biol Cell 1986; 57: 147-152
35. Rao GJ, Christe M. Inhibition of rabbit liver arylsulfatase B by phosphate esters. Biochim Biophys Acta 1994; 788: 58-61
36. Christianson TM, Starr CM, Zankel EC. Overexpression of inactive arylsulphatase mutants and in vitro activation by light-dependent oxidation with vanadate. Biochem J 2004; 283: 581-587
37. Yoo BC, Hong SH, Ku JL, Kim YH, Shin YK, Jang SG et al. Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol Life Sci 2009; 66: 350-364
38. Wang L, Inohara H, Pienta KJ, Raz A. Galectin-3 is a nuclear matrix protein which binds RNA. Biochem Biophys Res Commun 1995; 217: 292-303
39. Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC et al. MPS VI Study Group. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144: 574-580
40. Rauscher 3rd FJ, Sambucetti LC, Curran T, Distel RJ, Spiegelman BM. Common DNA binding site for FOS protein complexes and transcription factor AP-1. Cell 1998; 52: 471-480
41. Bhattacharyya S, Borthakur A, Dudeja PK, Tobacman JK. Carrageenan induces cell cycle arrest in human intestinal epithelial cells in vitro. J Nutr 2008; 138: 469-475